In EDS ansehen

Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study

Gespeichert in:
Bibliographische Detailangaben
Titel: Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study
Autoren: Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi
Weitere Verfasser: Hae Jin Kim, In Kyung Jeong, Kyu Yeon Hur, Soo-Kyung Kim, Jung Hyun Noh, Sung Wan Chun, Eun Seok Kang, Eun-Jung Rhee, Sung Hee Choi, Kang, Eun Seok
Quelle: Diabetes Metab J
Diabetes & Metabolism Journal, Vol 46, Iss 5, Pp 689-700 (2022)
Verlagsinformationen: Korean Diabetes Association, 2022.
Publikationsjahr: 2022
Schlagwörter: Blood Glucose, HDL, Lipoproteins, alogliptin, Uracil / analogs & derivatives, Diseases of the endocrine glands. Clinical endocrinology, Autoimmune Diseases, 03 medical and health sciences, Glycemic control, 0302 clinical medicine, Drug Therapy, Piperidines, Diabetes Mellitus, pioglitazone, Humans, Hypoglycemic Agents, glimepiride, Uracil, Alogliptin, Glycated Hemoglobin, Pioglitazone, Type 2, Blood Glucose Self-Monitoring, Glimepiride, Hypoglycemic Agents / adverse effects, Pioglitazone / therapeutic use, RC648-665, Lipids, Metformin, 3. Good health, Metformin* / therapeutic use, Cholesterol, Sulfonylurea Compounds, Treatment Outcome, type 2, diabetes mellitus, type 2, Diabetes Mellitus, Type 2, Combination, glycemic control, Original Article, Drug Therapy, Combination, Lipoproteins, HDL
Beschreibung: Background: The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-naïve or metformin failure.Methods: In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (n=35), ALO (n=31), or ALO-PIO (n=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks.Results: At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (–0.96%±0.17% vs. –0.37%±0.17% at week 12; –1.13%±0.19% vs. –0.18%±0.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms.Conclusion: ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or metformin failed T2DM patients.
Publikationsart: Article
Other literature type
Sprache: English
ISSN: 2233-6087
2233-6079
DOI: 10.4093/dmj.2021.0183
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/35295073
https://doaj.org/article/e82396ec1d0c4143a0356bf405815c2f
Rights: CC BY NC
CC BY NC ND
Dokumentencode: edsair.doi.dedup.....b0f948a8c352a03e0c7371d77dfabff0
Datenbank: OpenAIRE
Beschreibung
Abstract:Background: The choice of an optimal oral hypoglycemic agent in the initial treatment periods for type 2 diabetes mellitus (T2DM) patients remains difficult and deliberate. We compared the efficacy and safety of glimepiride (GLIM), alogliptin (ALO), and alogliptin-pioglitazone (ALO-PIO) in poorly controlled T2DM patients with drug-naïve or metformin failure.Methods: In this three-arm, multicenter, open-label, randomized, controlled trial, poorly controlled T2DM patients were randomized to receive GLIM (n=35), ALO (n=31), or ALO-PIO (n=33) therapy for 24 weeks. The primary endpoint was change in the mean glycosylated hemoglobin (HbA1c) levels at week 24 from baseline. Secondary endpoints were changes in HbA1c level at week 12 from baseline, fasting plasma glucose (FPG) levels, lipid profiles at weeks 12 and 24, and parameters of glycemic variability, assessed by continuous glucose monitoring for 24 weeks.Results: At weeks 12 and 24, the ALO-PIO group showed significant reduction in HbA1c levels compared to the ALO group (–0.96%±0.17% vs. –0.37%±0.17% at week 12; –1.13%±0.19% vs. –0.18%±0.2% at week 24). The ALO-PIO therapy caused greater reduction in FPG levels and significant increase in high-density lipoprotein cholesterol levels at weeks 12 and 24 than the ALO therapy. Compared to low-dose GLIM therapy, ALO-PIO therapy showed greater improvement in glycemic variability. The adverse events were similar among the three arms.Conclusion: ALO-PIO combination therapy during the early period exerts better glycemic control than ALO monotherapy and excellency in glycemic variability than low-dose sulfonylurea therapy in uncontrolled, drug-naïve or metformin failed T2DM patients.
ISSN:22336087
22336079
DOI:10.4093/dmj.2021.0183